Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy (NCT02312401) | Clinical Trial Compass
Active — Not RecruitingPhase 2
Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy
United States120 participantsStarted 2014-12
Plain-language summary
The purpose of this study is to better understand prostate cancer changes after radiation treatment, through magnetic resonance imaging (MRI). MRI is an imaging test that allows doctors to see prostate gland without any operation procedures. It can help identifying the tumors in the prostate. For patients with newly diagnosed prostate cancer, MRI may help doctors manage treatment better and sooner.
Who can participate
Age range18 Years
SexMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients with biopsy proven (completed and/or reviewed at MSK) adenocarcinoma of the prostate, who will undergo external beam radiotherapy using conventional fractionation IGRT including moderate hypofractionated radiation, low rate brachytherapy alone, brachytherapy (either high dose or low dose) combined with supplemental image guided radiation (including IGRT, EBRT, and SBRT), SBRT, or proton radiotherapy.
* Age ≥ 18 years old
* Baseline MP-MRI, which is obtained at MSKCC Main Campus on the 3-Tesla Philips MRI unit as part of the standard (clinical) staging assessment demonstrates at least one dominant or visible lesion which measures \> 0.5 cm in maximum axial diameter as assessed on T2-weighted images.
* No prior history of androgen deprivation therapy within the last month. However patients who will receive neoadjuvant and concurrent and adjuvant hormonal therapy will be eligible.
* Willing to come to MSK Main Campus for baseline and follow-up MP-MRIs.
Exclusion Criteria:
* History of radical prostatectomy
* Patients who are unwilling or unable to undergo MRI including patients with contraindications to MRI such as the presence of cardiac pacemakers or non-compatible intracranial vascular clips, claustrophobia, inability to lie flat for the duration of the study etc.
* Patients with a metallic hip implant, metallic implant or device in the pelvis or ferromagnetic fiducial beacons (Calypso) that might distort local magnetic field and compromise q…
What they're measuring
1
characterize the changes in tumor characteristics by functional imaging changes with post-treatment prostate biopsy outcomes
Timeframe: at 24 months after completion of radiotherapy